Skip to Main Content

Paper Details

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
Leuk Lymphoma
3
2020
Author NameAffiliation
Changchun DengCenter for Lymphoid Malignancies, Columbia University Irving Medical Center
  • 1 - 1

Datasets

Release 1.2